Publicaciones en colaboración con investigadores/as de Pfizer (United States) (2)

2008

  1. The exon 3-deleted/full-length growth hormone receptor polymorphism does not influence the effect of puberty or growth hormone therapy on glucose homeostasis in short non-growth hormone-deficient small-for-gestational-age children: Results from a two-year controlled prospective study

    Journal of Clinical Endocrinology and Metabolism, Vol. 93, Núm. 7, pp. 2709-2715

2006

  1. Exon 3-deleted/full-length growth hormone receptor polymorphism genotype frequencies in Spanish short small-for-gestational-age (SGA) children and adolescents (n = 247) and in an adult control population (n = 289) show increased fl/fl in short SGA

    Journal of Clinical Endocrinology and Metabolism, Vol. 91, Núm. 12, pp. 5038-5043